Teva’s AJOVY gains spotlight as first preventive migraine treatment for kids
The findings, from the SPACE study, paved the way for FDA approval of AJOVY for pediatric patients aged 6-17 years weighing 45 kilograms
The findings, from the SPACE study, paved the way for FDA approval of AJOVY for pediatric patients aged 6-17 years weighing 45 kilograms
BioNTech is positioning 2026 as a defining year in its transition toward a multi-product oncology company
CARsgen is working to transform outcomes for patients with solid tumors by advancing the potential of CAR T technologies
The trial also revealed statistically significant and clinically meaningful gains in key patient-reported outcomes
The FDA has set a Prescription Drug User Fee Act (PDUFA) target action date of June 10, 2026
The acquisition combines Firstsource’s market-leading AI and automation capabilities with TeleMedik’s operational footprint in Puerto Rico
Subscribe To Our Newsletter & Stay Updated